Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-9.67 Insider Own4.90% Shs Outstand79.74M Perf Week-0.87%
Market Cap7.47B Forward P/E- EPS next Y-2.79 Insider Trans-6.58% Shs Float74.02M Perf Month-22.02%
Income-715.10M PEG- EPS next Q-1.87 Inst Own95.00% Short Float17.10% Perf Quarter-27.86%
Sales380.80M P/S19.60 EPS this Y-77.80% Inst Trans0.00% Short Ratio13.56 Perf Half Y15.10%
Book/sh10.97 P/B8.53 EPS next Y55.90% ROA-39.50% Target Price192.24 Perf Year-22.65%
Cash/sh14.11 P/C6.64 EPS next 5Y-0.20% ROE-67.10% 52W Range72.05 - 158.80 Perf YTD-27.45%
Dividend- P/FCF- EPS past 5Y-23.40% ROI-47.10% 52W High-41.05% Beta1.99
Dividend %- Quick Ratio4.90 Sales past 5Y108.10% Gross Margin85.10% 52W Low29.94% ATR8.65
Employees743 Current Ratio5.50 Sales Q/Q18.60% Oper. Margin- RSI (14)43.40 Volatility7.01% 9.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-54.00% Profit Margin- Rel Volume1.82 Prev Close95.98
ShortableYes LT Debt/Eq0.83 EarningsFeb 26 AMC Payout- Avg Volume933.46K Price93.62
Recom1.70 SMA20-2.23% SMA50-14.62% SMA200-16.22% Volume1,702,420 Change-2.46%
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-31-20 06:06PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Mar-27-20 11:31AM  Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound? Zacks
Mar-24-20 02:20AM  Edited Transcript of SRPT earnings conference call or presentation 26-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-11-20 07:57PM  Do Hedge Funds Love Sarepta Therapeutics Inc (SRPT)? Insider Monkey -6.84%
Feb-28-20 06:20PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +6.32%
12:10PM  Sarepta Therapeutics, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Feb-27-20 10:47AM  Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates Zacks -5.25%
08:30AM  Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program GlobeNewswire
Feb-26-20 06:15PM  Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Feb-19-20 12:31PM  Analysts Estimate Sarepta Therapeutics (SRPT) to Report a Decline in Earnings: What to Look Out for Zacks
08:30AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020 GlobeNewswire
Feb-18-20 08:33AM  Sarepta Therapeutics (NASDAQ:SRPT) Has Debt But No Earnings; Should You Worry? Simply Wall St.
Feb-10-20 02:09PM  Shareholder Alert: Robbins LLP Reminds Investors Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders Business Wire
Feb-04-20 11:28AM  Vanguard Health Care Fund Adds 4 Stocks to Portfolio in 4th Quarter GuruFocus.com +5.05%
Feb-03-20 03:31AM  BTIG: New Data Could Propel These 3 Biotech Stocks Higher in 2020 TipRanks
Jan-31-20 06:16PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
05:00AM  Families of rare-disease patients take on drug development, but face uphill battle American City Business Journals
Jan-30-20 07:19AM  Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs Zacks
Jan-28-20 02:36PM  5 'Strong Buy' Biotech Stocks to Buy for 2020 Kiplinger +5.65%
Jan-23-20 05:15PM  Biotech Hits Two-Day Skid After FDA Sheds Light On Initial Drug Rejection Investor's Business Daily
02:25PM  Bragar Eagel & Squire is Investigating Certain Officers and Directors of Cardinal Health, CURO Group, Sarepta, and PG&E Corporation and Encourages Investors to Contact the Firm GlobeNewswire
Jan-22-20 11:48AM  New FDA documents shed light on agency's rejection of Sarepta drug American City Business Journals
Jan-20-20 08:54AM  Are Options Traders Betting on a Big Move in Sarepta (SRPT) Stock? Zacks
Jan-16-20 01:10PM  FDA Risks Sacrificing Its Standards for Speed Bloomberg
Jan-13-20 01:56PM  Does Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Pay Matter? Simply Wall St.
08:30AM  Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors GlobeNewswire
Jan-10-20 10:08AM  Applied Genetic Stock Up on Favorable Eye Therapy Study Data Zacks
Jan-09-20 09:12PM  Shareholder Alert: Robbins LLP Announces Sarepta Therapeutics, Inc. (SRPT) Sued for Misleading Shareholders Business Wire
Jan-06-20 08:30AM  Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-19 06:06PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-26-19 11:10AM  How Did Sarepta Therapeutics Inc (SRPT) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-24-19 12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
11:10AM  Gene therapy invented at Nationwide Children's lands $1.1B commercialization deal for Boston biotech American City Business Journals
09:15AM  Analysts: Roche Partnership Derisks Sarepta Investor Concerns Benzinga
09:04AM  Company News For Dec 24, 2019 Zacks
08:57AM  Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session Zacks
07:30AM  10 Biotech M&A Targets Under The Scanner For 2020 Benzinga
Dec-23-19 04:22PM  Sarepta Unveils $1.15 Billion Gene Therapy Deal  And Stock Pops Investor's Business Daily +7.46%
01:15PM  Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B Benzinga
10:11AM  Sarepta Signs Gene Therapy Agreement With Roche for $1.15B Zacks
08:48AM  Sarepta Stock Is Soaring on $1 Billion Deal With Roche Barrons.com
08:44AM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR Benzinga
01:15AM  Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal Reuters
01:00AM  Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 GlobeNewswire
Dec-19-19 10:27AM  One particular field of drug development could dominate M&A in 2020 American City Business Journals
Dec-18-19 08:38AM  Solid Biosciences stock are up on DMD study news MarketWatch
Dec-16-19 06:04PM  This Looks Like Just the Beginning for Sarepta Therapeutics (SRPT) Stock TipRanks
04:09PM  Why This Biotech's 55% Plunge Will Ultimately Benefit Its Biggest Rival Investor's Business Daily
09:27AM  Cambridge biotech's stock price tumbles on Duchenne drug failure American City Business Journals
Dec-13-19 04:11PM  Sarepta Rockets On Stunning Reversal For Previously Rejected Drug Investor's Business Daily +31.43%
12:22PM  Sareptas surprise FDA approval for rare disease drug excites investors MarketWatch
10:13AM  FDA approves Sarepta's muscular dystrophy drug Yahoo Finance Video
09:00AM  Sarepta Stock Is Spiking as FDA Reverses Course, Approving Drug Barrons.com
08:55AM  Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up Zacks
08:30AM  Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing GlobeNewswire
08:10AM  The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer Benzinga
04:36AM  Sarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy Treatment TheStreet.com
Dec-12-19 09:28PM  In an about face, FDA approves Sarepta's 2nd Duchenne drug American City Business Journals
06:43PM  Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug MarketWatch
06:19PM  Sarepta Therapeutics Announces FDA Approval of VYONDYS 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 GlobeNewswire
Dec-10-19 09:21AM  Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report? Zacks
07:00AM  Biotech accelerator teams with investment firm for $210M fund raise American City Business Journals
Dec-06-19 09:33AM  The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics Zacks
Dec-05-19 04:32PM  Astellas-Audentes Deal Likely to Ignite More Acquisitions GuruFocus.com
09:37AM  4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal Zacks
Dec-04-19 08:33PM  Did Hedge Funds Drop The Ball On Sarepta Therapeutics Inc (SRPT) ? Insider Monkey
Dec-03-19 11:53AM  The Gene Therapy Names Moving On The Audentes Buyout Deal Benzinga
10:19AM  Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Simply Wall St.
Nov-29-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-26-19 12:20PM  Why Did Farallon Capital Get Out of These 3 Biotech Stocks? TipRanks
Nov-15-19 08:57AM  Sarepta (SRPT) Stock Down Despite New $48M Gene Therapy Deal Zacks
Nov-14-19 04:15PM  This Biotech Stock Just Slumped On A $48 Million Gene-Therapy Deal Investor's Business Daily
01:27PM  Sarepta expands gene therapy push with $90M deal American City Business Journals
08:30AM  Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies GlobeNewswire
Nov-13-19 03:39AM  Edited Transcript of SRPT earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:03PM  Biotech Pops After Rival's Gene Therapy Halted By Regulators Investor's Business Daily +5.45%
02:44PM  3 Stocks That Wall Street Thinks Could Rise 40% or More TipRanks
10:56AM  FDA intervenes for 3rd time in Solid Biosciences' Duchenne drug tests American City Business Journals
Nov-08-19 02:33PM  Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates Zacks
09:45AM  Sareptas Earnings Show Promise, Analysts Say, but the Stock Is Flat Barrons.com
Nov-07-19 06:28PM  Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments GlobeNewswire
Nov-05-19 04:30PM  Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference GlobeNewswire
Oct-31-19 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
10:34AM  Earnings Preview: Sarepta Therapeutics (SRPT) Q3 Earnings Expected to Decline Zacks
Oct-29-19 10:55AM  CLASS ACTION UPDATE for SRPT, MTCH and INFY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:09AM  FINAL DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Oct-28-19 10:45AM  The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRPT, SNDL and TME ACCESSWIRE
09:31AM  SAREPTA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
08:50AM  FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Oct-25-19 04:15PM  CLASS ACTION UPDATE for SRPT, MDP and CC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM  DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 GlobeNewswire
01:15PM  SHAREHOLDER ALERT: SRPT MTCH CC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:03PM  SAREPTA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm Newsfile
01:01PM  Are Insiders Buying Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock? Simply Wall St.
12:16PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:20AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRPT, OLLI and CC ACCESSWIRE
09:50AM  FINAL DEADLINE ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Deadline: October 29, 2019 ACCESSWIRE
Oct-24-19 04:30PM  Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019 GlobeNewswire
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51, for the treatment of duchenne muscular dystrophy (DMD); and VYONDYS 53 for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Its products pipeline include Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD, micro-dystrophin gene therapy to treat peripheral neuromuscular diseases; SRP-9003, a gene therapy program for various types of limb-girdle muscular dystrophies; and LYS-SAF 302, a gene therapy program, which is in Phase 2/3 clinical trial to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; and GALGT2, a gene therapy program for the treatment of neuromuscular related disorders. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a license and collaboration agreement with Lysogene S.A., a gene therapy company for the treatment of orphan diseases of the central nervous system; license and collaboration agreement with Genethon to develop micro-dystrophin gene therapy products for the treatment of DMD; and a collaboration and license agreement with StrideBio, Inc. to develop in vivo adeno-associated virus based therapies. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Option Exercise28.88125,0003,610,443155,179Dec 17 08:00 PM
Howton David TEVP, General CounselDec 13Option Exercise21.4878,0001,675,439103,171Dec 17 08:01 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Option Exercise23.7032,706775,23243,867Dec 17 08:02 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Sale125.5042,0005,271,0001,867Dec 17 08:02 PM
Howton David TEVP, General CounselDec 13Sale125.5078,0009,789,00025,171Dec 17 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Sale125.50125,00015,687,50030,179Dec 17 08:00 PM
Howton David TEVP, General CounselNov 22Option Exercise16.1334,272552,66736,993Nov 26 08:01 PM
Howton David TEVP, General CounselNov 22Sale105.0025,0002,625,00011,993Nov 26 08:01 PM
Barry RichardDirectorSep 13Buy87.493,309289,5043,187,065Sep 16 08:00 AM
Barry RichardDirectorSep 12Buy87.491,691147,9503,183,756Sep 16 08:00 AM
BONNEY MICHAEL WDirectorSep 09Buy86.742,000173,4807,051Sep 09 02:18 PM
BEHRENS M KATHLEENDirectorSep 06Buy87.982,500219,950125,667Sep 06 02:13 PM
BEHRENS M KATHLEENDirectorSep 05Option Exercise7.805,00039,000123,167Sep 06 02:13 PM
Mahatme SandeshEVP, CFO & CBOAug 21Option Exercise23.85100,0002,385,000130,179Aug 22 07:20 PM
Barry RichardDirectorAug 20Buy99.325,000496,5933,182,065Aug 20 05:43 PM
Mahatme SandeshEVP, CFO & CBOAug 15Option Exercise24.739,754241,23230,179Aug 15 04:33 PM
Barry RichardDirectorAug 14Buy122.503,700453,2503,177,065Aug 14 04:38 PM
Barry RichardDirectorAug 12Buy122.501,300159,2503,173,365Aug 13 04:31 PM
INGRAM DOUGLAS SPresident & CEOAug 12Buy123.0716,2522,000,160432,197Aug 12 05:48 PM
Wigzell Hans Lennart RudolfDirectorMay 23Option Exercise7.8010,00078,00021,717May 24 08:03 PM
Wigzell Hans Lennart RudolfDirectorMay 23Sale120.0010,0001,200,00011,717May 24 08:03 PM